List of Excipients in Branded Drug CYCLOMYDRIL

« Back to Dashboard

Generic Drugs Containing CYCLOMYDRIL

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	cyclopentolate hydrochloride and phenylephrine hydrochloride	0065-0359	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	cyclopentolate hydrochloride and phenylephrine hydrochloride	0065-0359	BORIC ACID
Alcon Laboratories Inc	cyclopentolate hydrochloride and phenylephrine hydrochloride	0065-0359	EDETATE DISODIUM

What are the Most Frequently-Used Excipients in CYCLOMYDRIL?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	BORIC ACID
1	EDETATE DISODIUM

Cyclomydril Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Cyclomydril is a dual-agent ophthalmic solution containing cyclopentolate hydrochloride 0.2% and phenylephrine hydrochloride 1%. Its commercial value is tied to rapid pupil dilation for ophthalmic examinations, particularly when a single combination product can replace sequential administration of separate mydriatic agents. The main excipient opportunities are preservative-free packaging, improved pediatric tolerability, container-closure differentiation, and manufacturing efficiencies rather than new active-ingredient chemistry.

What is Cyclomydril and how does its formulation work?

Cyclomydril is an ophthalmic mydriatic containing an anticholinergic and an adrenergic agonist.

Attribute	Cyclomydril profile
Active ingredient 1	Cyclopentolate hydrochloride
Concentration	0.2%
Active ingredient 2	Phenylephrine hydrochloride
Concentration	1%
Dosage form	Sterile ophthalmic solution
Route	Topical ocular
Primary use	Pupil dilation and cycloplegia for ophthalmic examination
Regulatory pathway	Small-molecule prescription ophthalmic product
Generic pathway	Abbreviated New Drug Application, subject to FDA requirements
Biological product status	Not applicable

Cyclopentolate blocks muscarinic receptors in the iris sphincter and ciliary muscle. Phenylephrine stimulates alpha-adrenergic receptors in the iris dilator muscle. The combination supports mydriasis through complementary mechanisms.

Cyclomydril is commercially differentiated by convenience. A clinic can administer one product rather than coordinate separate cyclopentolate and phenylephrine products. The principal formulation risks are ocular irritation, preservative exposure, microbial contamination, pH control, osmolality, and dose uniformity.

What excipients are used in Cyclomydril?

The Cyclomydril prescribing information identifies a conventional aqueous ophthalmic formulation with buffering, tonicity, chelation, preservation, and pH-adjustment components. The listed inactive ingredients include benzalkonium chloride, boric acid, edetate disodium, potassium chloride, sodium citrate, and water for injection. Hydrochloric acid or sodium hydroxide may be used for pH adjustment, depending on manufacturing control strategy (DailyMed, n.d.).

Excipient function	Cyclomydril component	Commercial purpose
Preservative	Benzalkonium chloride	Controls microbial growth in a multidose container
Buffer	Boric acid and sodium citrate	Maintains ocularly acceptable pH and chemical stability
Chelator	Edetate disodium	Binds trace metals and can improve preservative performance
Tonicity agent	Potassium chloride	Adjusts osmolality
Vehicle	Water for injection	Provides sterile aqueous delivery
pH adjustment	Hydrochloric acid or sodium hydroxide	Establishes release-specification pH

This is a conventional preserved multidose design. The formulation does not depend on a proprietary excipient platform. Its defensibility therefore is more likely to arise from manufacturing controls, stability data, packaging, device integration, or specific formulation claims than from the base excipients themselves.

What excipient strategy is most attractive for Cyclomydril?

The strongest strategy is to separate the product into two commercial platforms:

1. A cost-efficient preserved multidose product for high-volume ophthalmology practices.
2. A preservative-free unit-dose or preservative-minimized product for pediatric, repeat-use, and ocular-surface-sensitive patients.

Preservative-free unit-dose strategy

Benzalkonium chloride is effective and widely used, but repeated ocular exposure can damage the tear film and corneal epithelium in susceptible patients. The risk is relevant in patients with dry eye, corneal disease, chronic topical therapy, or frequent examination-related dosing.

A preservative-free Cyclomydril alternative could use:

• Blow-fill-seal unit-dose ampoules.
• Sterile single-use polymer containers.
• A preservative-free multidose delivery system with validated microbial protection.
• Lower-fill-volume packaging to reduce waste and accidental reuse.

A unit-dose product would require a new container-closure and microbiological control strategy. It would not necessarily require a new active formulation if pH, osmolality, preservative removal, and stability remain acceptable. The commercial tradeoff is higher packaging cost and lower dose waste versus improved tolerability and institutional appeal.

Preservative-minimized strategy

A second option is to retain a multidose format while reducing benzalkonium chloride concentration or replacing it with another ophthalmic preservative. Candidate systems include polyquaternium-1, stabilized oxychloro complex, or oxidative preservative systems. Each would require compatibility, ocular-tolerability, antimicrobial-effectiveness, extractables, leachables, and stability studies.

Substitution is not a simple excipient swap. Benzalkonium chloride can interact with packaging surfaces and may contribute to antimicrobial performance through interactions with the chelator. Removing it can change microbial-risk profiles and container-closure requirements.

Buffer and tonicity optimization

The existing borate-citrate-potassium system is technically familiar and inexpensive. Commercial development could focus on:

• Narrower pH variability across shelf life.
• Lower ocular stinging at administration.
• Reduced precipitation or crystallization risk.
• Better compatibility with unit-dose polymer packaging.
• Improved stability under temperature excursions.
• More consistent osmolality across manufacturing lots.

The value of these changes would depend on measurable clinical or operational benefits. A formulation that reduces transient burning, for example, could support pediatric adoption and improve compliance during examinations. The product would still need to demonstrate equivalence or adequate clinical performance under the applicable FDA pathway.

Chelator optimization

Edetate disodium supports preservative performance and can reduce metal-catalyzed degradation. It may also affect container interactions and the stability of certain packaging materials.

A formulation without edetate could have a cleaner excipient profile but would require evidence that antimicrobial effectiveness and chemical stability remain acceptable. Retaining edetate is likely the lower-risk development choice for a preserved multidose product.

What formulations are protected by Cyclomydril’s patent estate?

Public product labeling establishes the composition and approved use, but it does not by itself establish enforceable patent protection. Excipient compositions may be protected by formulation patents, packaging patents, manufacturing-process patents, or method-of-use patents. Those rights must be distinguished from FDA approval and Orange Book listing.

For Cyclomydril, the most commercially relevant potential claim categories are:

Claim category	Relevance
Fixed-dose combination	Covers cyclopentolate and phenylephrine in a defined ratio or concentration range
Ophthalmic solution	Covers pH, osmolality, buffer system, preservative, or concentration limits
Preservative-free formulation	Could protect unit-dose or multidose delivery without benzalkonium chloride
Container-closure system	Could cover sterile packaging, dose delivery, or microbial-barrier performance
Manufacturing process	Could cover sterilization, compounding, filling, or stability-control steps
Method of use	Could cover dosing regimens, pediatric examination, or reduced administration frequency

The active ingredients are established small molecules. New composition-of-matter protection is therefore unavailable for the existing actives. Any later-filed protection would generally need to rely on a novel formulation, delivery system, manufacturing method, or clinically differentiated use.

What is the FDA and Orange Book status of Cyclomydril?

Cyclomydril is regulated as a prescription ophthalmic drug, not a biologic. Generic competition would proceed through the ANDA pathway rather than the biosimilar pathway. An ANDA applicant would generally need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA-specific requirements for the ophthalmic product.

Relevant FDA considerations include:

• Same active ingredients.
• Same strengths.
• Same dosage form and route.
• Equivalent quality attributes.
• Sterility assurance.
• Comparable labeling, subject to permitted ANDA differences.
• Appropriate in vitro and, where required, in vivo evidence.
• Container-closure suitability.
• Antimicrobial effectiveness for preserved multidose products.

Orange Book listings may include patents submitted by the reference-product sponsor and accepted for listing by FDA. Excipient information alone does not establish an Orange Book-listed patent. A generic applicant would assess any listed patents and regulatory exclusivities before filing a Paragraph IV certification.

Cyclomydril does not present a biosimilar opportunity because it is a chemically synthesized ophthalmic drug. The relevant competitive risks are generic ANDA filings, authorized-generic strategies, and reformulated combination products.

When does Cyclomydril lose exclusivity?

Cyclomydril’s market exclusivity depends on the status of any active FDA exclusivity and enforceable patent rights. The product’s commercial age means that original new-drug exclusivity would not ordinarily be the primary barrier today. The key risk assessment is therefore patent-specific.

Potential generic entry dates depend on:

1. The date of any Paragraph IV notice.
2. Whether the reference sponsor files patent litigation within the statutory period.
3. The availability of a 180-day first-filer period.
4. The scope and expiry of listed patents.
5. Any settlement terms.
6. FDA approval timing and manufacturing readiness.

Without an active patent barrier, an ANDA applicant could obtain approval when FDA review is complete and other statutory requirements are satisfied. A patent covering a narrow formulation would not necessarily block a non-infringing generic using different excipients.

What Paragraph IV challenges and litigation affect Cyclomydril?

A Paragraph IV challenge is legally relevant only if Cyclomydril has patents listed in the Orange Book. The applicant must certify that the listed patent is invalid, unenforceable, or will not be infringed. The reference sponsor may bring an infringement action under the Hatch-Waxman framework, potentially triggering a 30-month stay of FDA approval under applicable conditions (FDA, n.d.-a).

The commercial litigation questions are:

• Are any Cyclomydril patents currently listed?
• Do the claims cover the active combination, excipient system, or packaging?
• Can a generic avoid infringement through a different preservative or buffer?
• Has the sponsor entered a launch-at-risk settlement?
• Does the generic applicant qualify as a first Paragraph IV filer?

No litigation conclusion should be drawn solely from the product label. A formulation-focused generic may have greater design-around flexibility than a product that must copy a narrowly claimed delivery system.

How strong is the Cyclomydril patent estate?

The likely strength of the estate is moderate to weak for the basic formulation and potentially stronger for a newly patented delivery system.

Patent asset	Likely strength
Basic cyclopentolate/phenylephrine combination	Low if based on long-established active ingredients
Conventional borate-citrate formulation	Low to moderate, depending on claim specificity
Benzalkonium chloride preserved multidose solution	Low if readily designed around
Preservative-free unit-dose system	Moderate to strong if claims cover a validated package and formulation
Device-integrated delivery system	Moderate to strong if technically specific and commercially necessary
Manufacturing process	Moderate if process parameters produce unexpected stability or sterility benefits
Method of use	Variable; stronger if linked to a specific dosing or pediatric outcome

The best defensible commercial platform would combine a differentiated formulation with proprietary packaging and clinically relevant performance data. A patent directed only to a routine excipient substitution would face enablement, obviousness, and design-around risks.

What commercial opportunities exist for Cyclomydril?

Pediatric ophthalmology

Cyclomydril is relevant to pediatric eye examinations, where administration burden and ocular discomfort affect clinical workflow. A lower-irritation, preservative-free product could command a premium in pediatric practices if it reduces repeat dosing or improves acceptance.

Ambulatory surgery and diagnostic centers

A compact unit-dose presentation could improve inventory control, reduce contamination risk, and simplify administration in high-throughput settings. Hospitals may favor standardized single-use packaging even when acquisition cost is higher.

Specialty pharmacy and outpatient ophthalmology

A preservative-free product could target patients who already use chronic ophthalmic medicines or have ocular-surface disease. The opportunity is narrower than the general examination market but may support higher net pricing.

International markets

The combination may have commercial potential in countries where separate cyclopentolate and phenylephrine administration remains common. Geographic expansion would require country-specific registration, preservative requirements, packaging validation, and local labeling. The core regulatory strategy would still center on an established active combination rather than novel pharmacology.

Lifecycle management

Possible lifecycle products include:

• Preservative-free unit-dose Cyclomydril.
• Lower-volume high-concentration presentation, if clinically and regulatorily supportable.
• Ready-to-use sterile diagnostic kit.
• Combination kit with eyelid cleansing or post-dilation supplies.
• Tamper-evident multidose container.
• Packaging optimized for pediatric dosing.
• Formulation with reduced ocular-surface exposure to benzalkonium chloride.

A product kit may create commercial differentiation but would not necessarily produce drug-patent exclusivity. Its value would depend on workflow savings, reimbursement, purchasing contracts, and institutional adoption.

How does Cyclomydril compare with separate-component therapy?

Factor	Cyclomydril	Separate cyclopentolate plus phenylephrine
Administration burden	One product	Two products
Inventory	One SKU	Multiple SKUs
Dose flexibility	Fixed ratio	Adjustable
Preservative exposure	Determined by combination product	Depends on each product
Pediatric workflow	Operationally simpler	More administration steps
Formulation flexibility	Limited by fixed combination	Greater
Generic competition	Combination ANDA	Separate generic markets
Commercial differentiation	Packaging and tolerability	Price, concentration, and supply

The fixed combination is strongest where workflow efficiency matters. Separate-component therapy remains attractive where clinicians need to adjust the contribution of each active ingredient.

Key Takeaways

• Cyclomydril contains cyclopentolate hydrochloride 0.2% and phenylephrine hydrochloride 1%.
• Its conventional excipient system includes benzalkonium chloride, boric acid, edetate disodium, potassium chloride, sodium citrate, and water for injection.
• The clearest lifecycle opportunity is a preservative-free unit-dose product.
• A preservative-minimized multidose product is possible but requires extensive antimicrobial and packaging validation.
• Cyclomydril is a small-molecule ophthalmic drug, so generic ANDA competition is relevant and biosimilar competition is not.
• The strongest potential intellectual-property position would involve packaging, delivery, stability, or clinically differentiated formulation claims.
• Basic excipient substitution is unlikely to create a durable barrier unless it produces unexpected stability, tolerability, or manufacturing benefits.
• Commercial value is concentrated in pediatric ophthalmology, high-throughput diagnostic centers, ocular-surface-sensitive patients, and institutional packaging contracts.

FAQs

Can benzalkonium chloride be removed from Cyclomydril without changing the active ingredients?

Yes. A preservative-free formulation could retain the same active ingredients, but it would require a new sterility, packaging, stability, and microbial-control strategy.

Would a preservative-free Cyclomydril automatically receive new patent protection?

No. Patentability would depend on novelty, non-obviousness, enablement, and claim scope. Preservative removal alone may not support a strong patent unless combined with a non-obvious formulation or delivery system.

Is Cyclomydril eligible for biosimilar competition?

No. Cyclomydril is a chemically synthesized ophthalmic drug. Competition would generally involve generic drug applications rather than biosimilar applications.

What is the most important manufacturing barrier for a generic Cyclomydril product?

Sterility and container-closure performance are central barriers. A generic applicant must also control concentration uniformity, pH, osmolality, preservative effectiveness, particulate matter, and stability.

Could a generic avoid Cyclomydril patents by using different excipients?

Potentially. If enforceable claims cover a specific preservative, buffer, chelator, or packaging system, a generic may design around those limitations while maintaining the same active ingredients and strengths.

References

DailyMed. (n.d.). Cyclomydril: Cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution, prescribing information. U.S. National Library of Medicine.

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (n.d.-b). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

U.S. Food and Drug Administration. (2016). Quality considerations for topical ophthalmic drug products. Center for Drug Evaluation and Research.

United States Pharmacopeia. (2024). General chapter <771> Ophthalmic products. United States Pharmacopeial Convention.